Table 2

Overview of the study visits

Screening visitBaseline visitMonthFollow-up after 4 months of treatmentFollow-up 4 months after last treatment
1st2nd3rd4th
Anthropometry: body composition (weight, height, waist circumference, hip circumference), FG/acne, blood pressureXXX
Menstrual cycle diaryXXXXXXXX
Questionnaires: EQ-5D, SF36, PCOSQ, CPRS-SA*, Zung SAS*, Zung SDS*, IPAQ, TFEQ-R21, QEWP-R*XXX
Transvaginal ultrasoundXXX
Metabolic measures: fasting blood samples for glucose, insulin, HbA1c, c-peptide, OGTT.
Adipokines, lipid profile (LDL, HDL, NEFA) and inflammatory markers
XXX
DXAXXX
Endocrine measures: fasting blood samples for sex steroids, SHBG, LH, FSH, AMH, prolactin, TSH, T4XXX
Tissue and whole blood collectionXXX
  • *Only in China.

  • †Only in Sweden.

  • AMH, antimüllerian hormone; DXA, d ual-energy X-ray absorptiometry; EQ-5D, EuroQol-5 dimension; FG, Ferriman-Gallwey score; FSH, follicle-stimulating hormone; HDL, high-density lipoprotein; IPAQ, International Physical Activity Questionnaire; LDL, low-density lipoprotein; LH, luteinising hormone; NEFA, non-esterified fatty acids; NE, norepinephrine; OGTT, oral glucose tolerance test; PCOSQ, polycystic ovary syndrome questionnaire; QEWP-R, Questionnaire of Eating and Weight Patterns-Revised; SHBG, sex hormone-binding globulin; SF36, short form-36; TFEQ-R21, Three-Factor Eating Questionnaire; TSH, thyroid-stimulating hormone; T4, thyroxine; Zung SAS, Zung Self-Rating Anxiety Scale; Zung SDS, Zung Self-Rating Depression Scale.